The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most consistent .ndings associate subtle cognitive, particularly memory, de.cits with heavy ecstasy use. However, most studies have important inherent methodological problems. One of the most serious confounds is the widespread pattern of polydrug use which makes it dif.cult to relate the .ndings in user populations to one speci.c drug. The present paper represents a brief overview on this issue. The most commonly co-used substances are alcohol, cannabis and stimulants (amphetamines and cocaine). Stimulants are also neurotoxic upon both serotonergic and dopaminergic neurons. Hence, they may act synergistically with MDMA and enhance its long-term adverse effects. The interactions between MDMA and cannabis use may be more complex: cannabis use is a wellrecognized risk factor for neuropsychiatric disorders and it was shown to contribute to psychological problems and cognitive failures in ecstasy users. However, at the cellular level, cannabinoids have neuroprotective actions and they were shown to (partially) block MDMA-induced neurotoxicity in laboratory animals. In future, longitudinal and prospective research designs should hopefully lead to a better understanding of the relation between drug use and subclinical psychological symptoms or neurocognitive failures and, also, of questions around interactions between the various substances of abuse.
Bolla K I, McCann U D, Ricaurte G A (1998) Memory impairment in abstinent MDMA (‘Ecstasy’) users. Neurology51: 1532–1537
2.
Chan G C, Hinds T R, Impey S, Storm D R (1998) Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci18: 5322–5332
3.
Croft R J, Mackay A J, Mills A T, Gruzelier J G (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology153: 373–379
4.
Dafters R I, Hoshi R, Talbot A C (2004) Contribution of cannabis and MDMA (‘ecstasy’) to cognitive changes in long-term polydrug users. Psychopharmacology173: 405–410
5.
Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacology16: 627–633
6.
Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology173: 398–404
7.
Daumann J, Schnitker R, Weidemann J, Schnell K, Thron A, Gouzoulis-Mayfrank E (2003) Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport14: 1983–1987
8.
Degenhardt L, Hall W, Lynskey M (2003) Exploring the association between cannabis use and depression. Addiction98: 1493–1504
9.
Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for longterm neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology54: 1344–1349
10.
Fox H C, Parrott A C, Turner J J (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol15: 273–281
11.
Gamma A, Frei E, Lehmann D, Pascual-Marqui R D, Hell D, Vollenweider F X (2000) Mood state and brain electric activity in ecstasy users. Neuroreport11: 157–162
12.
Gonzalez R, Rippeth J D, Carey C L, Heaton R K, Moore D J, Schweinsburg B C, Cherner M, Grant I (2004) Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend76: 181–190
13.
Gouzoulis-Mayfrank E, Daumann J (in press) Neurotoxicity of methylenedioxyamphetamines (MDMA; Ecstasy) in humans: how strong is the evidence? Addiction
14.
Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003) Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry27: 819–827
15.
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H J, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry68: 719–725
16.
Green A R, Mechan A O, Elliott J M, O'shea E, Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev55: 463–508
17.
Grundy R I, Rabuffetti M, Beltramo M (2001) Cannabinoids and neuroprotection. Mol Neurobiol24: 29–51
18.
Hall W, Degenhardt L, Teesson M (2004) Cannabis use and psychotic disorders: an update. Drug Alcohol Rev23: 433–443
19.
Hamelink C, Hampson A, Wink D A, Eiden L E, Eskay R L (2005) Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther314: 780–788
20.
Hampson A J, Grimaldi M (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci13: 1529–1536
21.
Hampson A J, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA95: 8268–8273
22.
Hanson G R, Rau K S, Fleckenstein A E (2004) The methamphetamine experience: a NIDA partnership. Neuropharmacology47(Suppl. 1): 92–100
23.
Hatzidimitriou G, McCann U D, Ricaurte G A (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci19: 5096–5107
24.
Jacobsen L K, Mencl W E, Westerveld M, Pugh K R (2004) Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci1021: 384–390
25.
Kanayama G, Rogowska J, Pope H G, Gruber S A, Yurgelun-Todd D A (2004) Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology176: 239–247
26.
Lawton-Craddock A, Nixon S J, Tivis R (2003) Cognitive efficiency in stimulant abusers with and without alcohol dependence. Alcohol Clin Exp Res27: 457–464
27.
Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey S G (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet363: 1579–1588
28.
McCann U D, Ricaurte G A (2004) Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev27: 821–826
29.
McCann U D, Eligulashvili V, Ricaurte G A (2000) (+/-)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology42: 11–16
30.
McCann U D, Mertl M, Eligulashvili V, Ricaurte G A (1999) Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users: a controlled study. Psychopharmacology143: 417–425
31.
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998a) Positron emission tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurons in human beings. Lancet352: 1433–1437
32.
McCann U D, Wong D F, Yokoi F, Villemagne V, Dannals R F, Ricaurte G A (1998b) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci18: 8417–8422
33.
Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med8: 58–61
34.
Milani R M, Parrott A C, Turner J J D (2002) Cannabis use in ecstasy users. Addiktologie1: 67–68
35.
Montgomery C, Fisk J E, Newcombe R (2005) The nature of ecstasygroup related deficits in associative learning. Psychopharmacology180: 141–149
36.
Morgan M J (1998) Recreational use of ‘ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology19: 252–264
37.
Morgan M J (1999) Memory deficits associated with recreational use of ‘ecstasy’ (MDMA). Psychopharmacology141: 30–36
38.
Morgan M J, McFie L, Fleetwood H, Robinson J A (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology159: 294–303
39.
Morley K C, Li K M, Hunt G E, Mallet P E, McGregor I S (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (‘Ecstasy’) in rats. Neuropharmacology46: 954–965
40.
Ornstein T J, Iddon J L, Baldacchino A M, Sahakian B J, London M, Everitt B J, Robbins T W (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology23: 113–126
41.
Parrott A C, Milani R M, Turner J J (2002) Ecstasy and the SCL-90 findings: a reply to Cole et al.Psychopharmacology162: 218–222
42.
Parrott A C, Sisk E, Turner J J (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend60: 105–110
43.
Parrott A C, Milani R M, Parmar R, Turner J D (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology159: 77–82
44.
Patton G C, Coffey C, Carlin J B, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. BMJ325: 1195–1198
45.
Pope H G Jr, Gruber A J, Hudson J I, Huestis M A, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry58: 909–915
46.
Reneman L, Booij J, Schmand B, van Den B W, Gunning B (2000) Memory disturbances in ‘Ecstasy’ users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology148: 322–324
47.
Reneman L, Lavalaye J, Schmand B, de Wolff F A, van Den B W, den Heeten G J, Booij J (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’): preliminary findings. Arch Gen Psychiatry58: 901–906
48.
Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma J B, Gunning B, den Heeten G J, van Den B W (2002) Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study – preliminary report. Psychopharmacology159: 335–340
49.
Ricaurte G A, Yuan J, McCann U D (2000) (+/-)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology42: 5–10
50.
Riehman K S, Iguchi M Y, Anglin M D (2002) Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment. Psychol Addict Behav16: 333–337
Rodgers J, Buchanan T, Scholey A B, Heffernan T M, Ling J, Parrott A (2001) Differential effects of Ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol16: 619–625
53.
Roiser J P, Sahakian B J (2004) Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology173: 411–417
54.
Salo R, Nordahl T E, Possin K, Leamon M, Gibson D R, Galloway G P, Flynn N M, Henik A, Pfefferbaum A, Sullivan E V (2002) Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res111: 65–74
55.
Scholey A B, Parrott A C, Buchanan T, Heffernan T M, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav29: 743–752
56.
Schuster P, Lieb R, Lamertz C, Wittchen H U (1998) Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res4: 75–82
57.
Seiden L S, Sabol K E (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr163: 251–276
58.
Simon N G, Mattick R P (2002) The impact of regular ecstasy use on memory function. Addiction97: 1523–1529
59.
Simon S L, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict9: 222–231
60.
Simon S L, Domier C P, Sim T, Richardson K, Rawson R A, Ling W (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis21: 61–74
61.
Solowij N, Stephens R S, Roffman R A, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA287: 1123–1131
62.
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology167: 85–96
63.
van der Stelt M, Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med7: 37–50
64.
van der Stelt M, Veldhuis W B, Maccarrone M, Bar P R, Nicolay K, Veldink G A, Di Marzo V, Vliegenthart J F (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol26: 317–346
65.
Volkow N D, Chang L, Wang G J, Fowler J S, Franceschi D, Sedler M J, Gatley S J, Hitzemann R, Ding Y S, Wong C, Logan J (2001a) Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry158: 383–389
66.
Volkow N D, Chang L, Wang G J, Fowler J S, Leonido-Yee M, Franceschi D, Sedler M J, Gatley S J, Hitzemann R, Ding Y S, Logan J, Wong C, Miller E N (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry158: 377–382
67.
Voytek B, Berman S M, Hassid B D, Simon S L, Mandelkern M A, Brody A L, Monterosso J, Ling W, London E D (2005) Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse57: 113–115
68.
Wang G J, Volkow N D, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler J S (2004) Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry161: 242–248
69.
Wareing M, Fisk J E, Murphy P N (2000) Working memory deficits in current and previous users of MDMA (‘ecstasy’). Br J Psychol91: 181–188
70.
Winstock A R, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend64: 9–17
71.
Woods S P, Rippeth J D, Conover E, Gongvatana A, Gonzalez R, Carey C L, Cherner M, Heaton R K, Grant I (2005) Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology19: 35–43
